Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03343327Phase 1Completed

A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects

Role: collaborator

NCT02966652Phase 1Completed

Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism

Role: collaborator

NCT03311932Phase 1Completed

A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects

Role: collaborator

NCT03178214Phase 1Completed

Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration

Role: collaborator

All 4 trials loaded